Corbus Pharmaceuticals (CRBP) shares slumped 10% in recent trading Friday despite reporting what it described as encouraging data from the "Western" clinical trial of its CRB-701 anti-body drug conjugate.
A total of 26 patients with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression were evaluable at December 2024 data cut point in the US and UK study.
The phase 1 Western dose escalation study's results mirrored those from the China study in terms of safety, tolerability, and pharmacokinetics, the company said. No dose-limiting adverse events were reported from both studies, it said.
However, Corbus reported one response in four metastatic urothelial cancer patients dosed in the Western study, compared with the China study's 44% involving nine patients.
The company on Friday presented the data from the Western study at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Price: 8.53, Change: -0.95, Percent Change: -10.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.